NIDEK CO., LTD., a global leader in the design, manufacture, and distribution of ophthalmic, optometric, and lens edging equipment, announced the launch of the Mirante Scanning Laser Ophthalmoscope
The Mirante is the ultimate multimodal fundus imaging platform that combines high definition SLO and OCT with ultra wide field imaging. The multimodal platform captures high quality color images, fluorescein angiography (FA), indocyanine green angiography (ICG), fundus autofluorescence (FAF), unique Retro mode images, OCT scan, and OCT-Angiography.
The optional wide-field adapter enables 163° ultra wide field imaging with a single image capture. The ultra wide field modalities of colour, FA, ICG, and Retro mode allow detailed evaluation of pathologies from the fovea to the extreme periphery. Combined with 4,096 x 4,096 pixels imaging quality, ultra 4K HD, the Mirante achieves a wider, enhanced view of the retinal structure and vasculature with unparalleled clarity. The new Flex Track algorithm corrects image distortion due to unstable fixation and enhances image averaging quality.
For colour imaging, three separate RGB detectors simultaneously scan different depths of the retina with red, green, and blue wavelengths, producing unsurpassed colour and allowing fine adjustment of the histogram.
Dynamic blood flow using FA and ICG can be recorded with the Mirante. It also allows simple, simultaneous acquisition of FA and ICG images.
The unique Retro mode modality is a non-invasive technique for visualizing pathologies deeper than the retinal pigment epithelium and detecting pathologic changes in the choroid. The pseudo-3D images from Retro mode allow better clinical appreciation of the extent of the pathology.
High definition OCT images can be acquired for a maximum 16.5 x 12 mm area, allowing a wide, detailed assessment from the vitreous to choroid in a single shot. The Mirante also offers options for AngioScan OCT-Angiography and an anterior segment OCT adapter.
“Multimodal retinal imaging is increasingly playing a key role for comprehensive evaluation of retinochoroidal diseases.” says Motoki Ozawa, President and CEO of NIDEK CO., LTD. “Addressing this demand, NIDEK developed the Mirante with new and existing technologies in our portfolio, and we have confidence that this platform offers a versatile solution for clinicians.”
